Lactate dehydrogenase isoenzymes in patients with acute exacerbation of chronic obstructive pulmonary disease: An exploratory cross-sectional study
Datum
2021Language
en
Schlagwort
Zusammenfassung
We aimed to evaluate differences in serum lactate dehydrogenase (LDH) isoenzymes between patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and other lower respiratory tract infections (LRTIs). Based on self-reported COPD diagnosis, 71 participants were divided into AECOPD (n = 38, 29 males, mean age 70.5 years) and LRTI (n = 33, 12 males, mean age 70.4 years) groups. Information on demographics, comorbidities, and COPD severity markers, as well as arterial blood gases and laboratory data were collected, while serum LDH electrophoresis was performed to examine the LDH isoenzymes. Adjusting for sex, age, comorbidities, degree of hypoxemia, inflammation markers, muscle and myocardial enzymes, and total serum LDH, the mean differences (95 % confidence intervals) in the ratios of serum LDH isoenzymes to total serum LDH between groups (LDHxAECOPD − LDHxLRTI) were statistically significant for LDH1 [4.9 (1.4 to 8.3)], LDH2 [3.0 (0.1 to 5.8)], LDH3 [−4.3 (−6.3 to −2.3)], and LDH4 [−3.2 (−4.9 to −1.5)]. A sum of LDH3 and LDH4 ratios below 29 % had the highest discriminative ability to classify a subject in the AECOPD group (AUC 0.841, sensitivity 76 %, specificity 87 %). Aerobic metabolic adaptive mechanisms in respiratory muscles during AECOPD could explain the above differences. © 2020 Elsevier B.V.
Collections
Verwandte Dokumente
Anzeige der Dokumente mit ähnlichem Titel, Autor, Urheber und Thema.
-
Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19
Dalekos G.N., Stefos A., Georgiadou S., Lygoura V., Michail A., Ntaios G., Samakidou A., Giannoulis G., Gabeta S., Vlychou M., Petinaki E., Leventogiannis K., Giamarellos-Bourboulis E.J., Gatselis N.K. (2021)Aims Infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may lead to the development of severe respiratory failure. In hospitalized-patients, prompt interruption of the virus-driven inflammatory process ... -
Circulating suPAR associates with severity and in-hospital progression of COVID-19
Chalkias A., Skoulakis A., Papagiannakis N., Laou E., Tourlakopoulos K., Pagonis A., Michou A., Ntalarizou N., Mermiri M., Ragias D., Bernal-Morell E., Cebreiros López I., García de Guadiana-Romualdo L., Eugen-Olsen J., Gourgoulianis K., Pantazopoulos I., Chalkias A., Skoulakis A., Laou E., Michou A., Ntalarizou N., Mermiri M., Ragias D., Tourlakopoulos K., Pagonis A., Gourgoulianis K., Pantazopoulos I., Papagiannakis N., Kampolis C., García de Guadiana-Romualdo L., Albaladejo-Otón M.D., Rodríguez Mulero M.D., Galindo Martínez M., Hernández Olivo M., Campos Rodríguez V., Cebreiros López I., Arnaldos Carrillo M., Noguera Velasco J.A., Pascual Figal D.A., Bernal-Morell E., Alcaraz García A., Alcaraz García M.J., Martínez Martínez M., Esteban-Torrella P., Sancho-Rodríguez N., Eugen-Olsen J., for the SPARCOL Investigators (2022)Background: COVID-19 disease progression is characterized by hyperinflammation and risk stratification may aid in early aggressive treatment and advanced planning. The aim of this study was to assess whether suPAR and other ... -
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: A multicenter national study by the Greek Myeloma Study Group
Katodritou E., Terpos E., Delimpasi S., Kotsopoulou M., Michalis E., Vadikolia C., Kyrtsonis M.-C., Symeonidis A., Giannakoulas N., Vadikolia C., Michael M., Kalpadakis C., Gougopoulou T., Prokopiou C., Kaiafa G., Christoulas D., Gavriatopoulou M., Giannopoulou E., Labropoulou V., Verrou E., Kastritis E., Konstantinidou P., Anagnostopoulos A., Dimopoulos M.A. (2018)We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty percent of patients were treated upfront with novel agent-based ...